ArticleThe clinical respiratory journal2023

Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive-stage small-cell lung cancer patients (DURABLE study).

Bo Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.